cell genesys (WKN 888140) Eure Meinung bitte! - 500 Beiträge pro Seite
eröffnet am 28.07.00 09:23:38 von
neuester Beitrag 27.11.01 21:23:18 von
neuester Beitrag 27.11.01 21:23:18 von
Beiträge: 34
ID: 198.483
ID: 198.483
Aufrufe heute: 0
Gesamt: 2.718
Gesamt: 2.718
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 51 Minuten | 3804 | |
| 01.05.24, 18:36 | 2389 | |
| vor 33 Minuten | 2320 | |
| gestern 19:24 | 1915 | |
| vor 5 Minuten | 1616 | |
| vor 1 Stunde | 1511 | |
| gestern 18:35 | 1377 | |
| vor 37 Minuten | 1335 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.001,60 | +0,59 | 240 | |||
| 2. | 2. | 168,20 | +0,08 | 87 | |||
| 3. | 3. | 9,7000 | +12,27 | 75 | |||
| 4. | 14. | 6,1400 | -1,35 | 69 | |||
| 5. | 11. | 0,1865 | 0,00 | 52 | |||
| 6. | 7. | 0,8750 | -12,50 | 47 | |||
| 7. | 12. | 0,1561 | +2,97 | 38 | |||
| 8. | 6. | 2.302,50 | 0,00 | 36 |
Feedback
@alle Biotech-Spezialisten:
was haltet ihr von cell genesys? wird auf www.biotech-world.de beschrieben. Mich würde mal Eure Meinung dazu interessieren.
Danke!
Hermi
was haltet ihr von cell genesys? wird auf www.biotech-world.de beschrieben. Mich würde mal Eure Meinung dazu interessieren.
Danke!
Hermi
hallo,hermi,bist du im rechenzentrum hamburg
@GrossmeisterB
Nein, bin ich nicht.
Sag mal, kommt Dein Pseudo aus einer amerikanischen sit-com,
Familienname Bundy?
Gruss Hermi
Nein, bin ich nicht.
Sag mal, kommt Dein Pseudo aus einer amerikanischen sit-com,
Familienname Bundy?
Gruss Hermi
Cell Genesys (CEGE)ist ein LONG TERM WINNER !!!
CEGE hat 12% Anteil an Abgenix (ABGX) Der innere Wert (Total Assets) ist momentan USD 25.--(man kann also noch zu Discount kaufen)
CEGE hat bereits ueber 200 gewaehrte Patente und weitere300 in der Pipeline!
Also, zur Tat schreiten und JETZT kaufen, die Nasdaq ist total
ueberVERkauft, Bald in ein Herbst-Rally starten!
ich bin durchschaut
Trading Spotlight
CEGE hat eine Menge Patente auf gentherapeutische Verfahren (virale Vektoren usw.) und dürfte langfristig enorme Lizenzzahlungen erhalten. Krebsmedikament in Phase II wird noch ein Weilchen bis zur Marktreife brauchen. 7$ pro Aktie Cash und 12,8% an, deckt Kurs ab (s. oben). Lizenzzahlungen aus GA-EPO-Verkäufen von Aventis/TKTX möglich. gholzbauer rating: strong buy, long-term. Wenn sie fallen, nachkaufen!
war im Wochenende und konnte erst jetzt wieder an den Computer
@gholzbauer:
Herzlichen Dank für Deine Infos
@biotechholder:
Genauso herzlichen Dank
welche Werte würdet Ihr denn noch so empfehlen? Ich möchte gerne
investieren und nicht zocken.
gruss hermi
@gholzbauer:
Herzlichen Dank für Deine Infos
@biotechholder:
Genauso herzlichen Dank
welche Werte würdet Ihr denn noch so empfehlen? Ich möchte gerne
investieren und nicht zocken.
gruss hermi
33E (+7E), US vorbörslich >30$
Cell Genesys und GPC
Biotech AG berichten über erfolgreiche präklinische Ergebnisse eines
neuen Gentherapieansatzes gegen Krebs
- Neuartiges wachstumshemmendes Fusionsgen wirksam gegen viele
Tumorarten -
Cell Genesys und GPC Biotech AG gaben heute bekannt,
dass ein innovativer Gentherapieansatz unter Benutzung eines
neuartigen Fusionsgens p27/p16 in der Lage war, eine
Vielzahlverschiedener Krebsarten im Rahmen von vorklinischen Studien
zu zerstören. Dabei zeigte das p27/p16 Fusionsgen eine 5- bis 50-fach
stärkere Anti-Tumor-Aktivität als die "Tumor-Suppressor"-Gene p16 und
p27 alleine. Weiter konnte gezeigt werden, dass die tumorzerstörende
Aktivität der p27/p16 Gentherapie spezifisch auf Krebszellen wirkt
und benachbartes gesundes Gewebe nicht beeinträchtigt. Die
Gentherapie mit p27/p16 konnte das Tumorwachstum in etwa 50% der
behandelten Mäuse stoppen - ein statistisch hoch signifikantes
Resultat (p=0.002). In 12 von 14 menschlichen Tumortypen konnte der
Zelltod der Krebszellen ausgelöst worden, unabhängig davon, ob die
Tumorzellen normales oder mutiertes p53 Gen enthielten, p53 ist ein
natürlich vorkommendes Tumor-Suppressor-Gen, das normalerweise gegen
die Entstehung von Krebs schützt, das aber in mehr als 50%
menschlicher Tumore mutiert und daher inaktiv ist. Die meisten bisher
bekannten Krebstherapien erfordern die Anwesenheit eines aktiven p53
in der Tumorzelle und sind dadurch deutlich in ihrer Wirksamkeit
eingeschränkt.
Weitere Informationen: GPC Biotech AG Petra
Bassen Head of Investor Relations & Corporate Communications
Tel : +49 89 8565 2691 Fax: +49 89 8565 2610 ir@gpc-biotech.com
or visit our homepage at: www.gpc-biotech.com Martinsried/München,
August 23, 2000 Der Vorstand / The Management Board
Cell Genesys and GPC Biotech Report Successful Preclinical Studies for Novel Cancer Gene Therapy Unique Growth Inhibitory Fusion Gene Can Target Multiple Tumor Types
FOSTER CITY, Calif. and MUNICH, Germany, Aug 23, 2000 /PRNewswire via COMTEX/ -- Cell Genesys, Inc. (Nasdaq: CEGE chart, msgs) announced today, in collaboration with GPC Biotech AG (Frankfurt:GPC) that a novel gene therapy employing a unique, proprietary fusion gene, referred to as p27/p16, was capable of killing multiple cancer cell types in preclinical studies. Of particular significance was that tumor cell death was induced in twelve of fourteen human tumor cell types regardless of whether the cells contained a normal or mutated p53 gene-a naturally occurring tumor suppressor gene which typically protects against cancer but is mutated in more than 50 percent of all human cancers. Additionally, the tumor cell killing with p27/p16 gene therapy was selective and did not affect surrounding normal tissue. These data were published in the August issue of the journal, Molecular Therapy, by James G. McArthur, Ph.D., and colleagues at Cell Genesys and GPC Biotech.
In the reported work, a number of preclinical studies were conducted to evaluate gene therapy with p27/p16, a unique fusion gene comprised of two cell cycle inhibitory genes, p27 and p16, which control tumor growth by blocking tumor cell division and inducing tumor cell death. In a series of studies in human tumor models in mice, the p27/p16 gene was delivered to the tumor using an adenoviral gene delivery system. Gene therapy with the p27/p16 fusion gene blocked tumor progression in approximately 50 percent of the treated animals, a result that was highly statistically significant in these experiments (p= .002). The fusion gene demonstrated five to 50-fold greater tumoricidal activity than either of the individual p16 and p27 genes. In addition, p27/p16 gene therapy demonstrated microscopic evidence of an antiangiogenic effect against the tumor with inhibition of tumor blood vessel formation.
"We are encouraged by the preclinical studies performed to date with p27/p16 gene therapy particularly with respect to the breadth of antitumor activity and selectivity for tumor as opposed to normal cells," stated Joseph J. Vallner, Ph.D., executive vice president and chief operating officer at Cell Genesys. "The success of this program together with our expanding research efforts in cancer gene therapy involving antiangiogenesis demonstrates Cell Genesys` growing pipeline of potential cancer products and is an important complement to our program in human clinical trials of GVAX(R) cancer vaccines."
"This project exemplifies the substantial value of GPC Biotech`s extensive estate of issued patents in the field of tumor suppressor genes and growth control, including p27/p16 which is derived from the tumor suppressor genes p16 and p27 and was originally engineered by scientists at Mitotix Inc., now GPC Biotech Inc. In the hands of Cell Genesys with its world class expertise in gene therapy, the p27/p16 fusion gene has exciting potential in the treatment of both cancer and cardiovascular disease," stated Muzammil Mansuri, Ph.D., executive vice president and chief operating officer for GPC Biotech`s Cambridge, MA site.
In 1998, Cell Genesys exclusively licensed a family of cell cycle inhibitor genes from Mitotix, Inc., which was recently acquired by GPC Biotech AG (Munich, Germany). The licensed genes include p16, p27 and novel p27/p16 fusion genes. The collaboration was initially focused on the development of cardiovascular gene therapy products and was expanded to include cancer gene therapy products in 1999. The p16 and p27 cell cycle inhibitor genes, also referred to as cyclin dependent kinase inhibitors (CDKi), play a key role in the regulation of cellular division. Moreover, the p16 gene, a known tumor suppressor gene, has been shown to be missing or mutated in many important cancers. Gene therapy employing p16, p27 and/or the p27/p16 fusion gene could therefore potentially be used to treat a variety of cancers. In addition, such gene therapy may have applicability to the treatment of other diseases characterized by abnormal cell growth such as restenosis, a condition resulting from the excessive growth of blood vessel smooth muscle cells which can arise after angioplasty for coronary artery disease and other cardiovascular disorders. GPC Biotech and Cell Genesys have an ongoing research collaboration for the optimization and testing of the p16, p27 and p27/p16 fusion genes.
Cell Genesys is focused on the development and commercialization of cancer vaccines and gene therapies to treat major, life-threatening diseases. The company is conducting two multicenter Phase II human clinical trials for its GVAX(R) cancer vaccine in prostate cancer, a multicenter Phase I/II trial of GVAX(R) vaccine in lung cancer and expects to initiate additional GVAX(R) vaccine trials in pancreatic cancer, myeloma and leukemia during the coming year. Preclinical stage programs include gene therapy for hemophilia, cancer, cardiovascular disorders and Parkinson`s disease. Cell Genesys` assets outside gene therapy include its approximately 12 percent ownership of Abgenix, Inc. and the company`s licensing program in gene activation technology. For additional information, please visit the company`s web site at www.cellgenesys.com.
GPC Biotech AG is a genomics-driven drug discovery company focused on applying a number of proprietary genomic, proteomic and drug discovery technologies to accelerate the identification and validation of novel drug targets for development of mechanism-based drugs in oncology, infectious diseases and immunology. The proprietary technologies provide life-science companies with a unique "one-stop-shop" resource by fully integrating functional genomics, proteomics and bioinformatics into drug discovery. GPC Biotech has globally-leading cell cycle expertise and a broad intellectual property position with 40 issued patents and over 120 patents pending. Drug discovery alliance partners include: Aventis Pharma, Bayer AG, DuPont Pharmaceuticals, Boehringer Ingelheim, Byk Gulden, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems, MorphoSys, Genetica, Gene Alliance, Karo Bio USA and Atugen. GPC Biotech AG is headquartered in Munich, Germany with US subsidiaries GPC Biotech Inc. in Cambridge, MA and GPC Biotech USA in Princeton, NJ. For further information, please visit the corporate web site at www.gpc-biotech.com.
Statements made herein, other than statements of historical fact, including statements about Cell Genesys` progress and results of cancer and other preclinical studies, clinical trials, marketability and success of potential products and nature and growth of product pipelines, corporate partnerships, licenses and intellectual property including that pertaining to gene delivery technology and the company`s patent portfolio are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the continuation of research collaborations with GPC Biotech AG and others, the success of research and development programs, results achieved in future preclinical studies and clinical trials, the regulatory approval process, competitive technologies and products, the scope and validity of patents, corporate partnerships and additional financings. For information about these and other risks which may affect Cell Genesys, please see the company`s Annual Report on Form 10-K dated March 30, 2000 as well as Cell Genesys` reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission.
This press release may contain certain views and forward-looking statements, which include terms such as "believes", "assumes", "expects", "intends" and similar language. Such views and forward-looking statements are based upon currently available information and are subject to known and unknown risks, uncertainties and other factors, as a result of which the actual future financial performance, development or performance of GPC Biotech or the business of GPC Biotech may substantially deviate from the anticipated events presented herein. Such factors include, but are not limited to, the following: competition from other companies, GPC Biotech`s capital needs, financing costs, changes in operating costs, the ability to find and retain qualified staff, uncertainties relating to drug development and obtaining regulatory approvals, uncertainties related to the operations of GPC Biotech and other factors identified in GPC Biotech`s Offering Circular dated May 30, 2000. GPC Biotech is not undertaking any obligation to release publicly any updates to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.
CONTACT: Jennifer Cook Williams, Manager, Corporate Communications of Cell Genesys, Inc., 650-425-4542; or Petra Bassen, Investor Relations and Corporate Communications of GPC Biotech AG in Germany, +49-89-85-65-26-91
Source: Cell Genesys, Inc.
Cell Genesys und GPC
Biotech AG berichten über erfolgreiche präklinische Ergebnisse eines
neuen Gentherapieansatzes gegen Krebs
- Neuartiges wachstumshemmendes Fusionsgen wirksam gegen viele
Tumorarten -
Cell Genesys und GPC Biotech AG gaben heute bekannt,
dass ein innovativer Gentherapieansatz unter Benutzung eines
neuartigen Fusionsgens p27/p16 in der Lage war, eine
Vielzahlverschiedener Krebsarten im Rahmen von vorklinischen Studien
zu zerstören. Dabei zeigte das p27/p16 Fusionsgen eine 5- bis 50-fach
stärkere Anti-Tumor-Aktivität als die "Tumor-Suppressor"-Gene p16 und
p27 alleine. Weiter konnte gezeigt werden, dass die tumorzerstörende
Aktivität der p27/p16 Gentherapie spezifisch auf Krebszellen wirkt
und benachbartes gesundes Gewebe nicht beeinträchtigt. Die
Gentherapie mit p27/p16 konnte das Tumorwachstum in etwa 50% der
behandelten Mäuse stoppen - ein statistisch hoch signifikantes
Resultat (p=0.002). In 12 von 14 menschlichen Tumortypen konnte der
Zelltod der Krebszellen ausgelöst worden, unabhängig davon, ob die
Tumorzellen normales oder mutiertes p53 Gen enthielten, p53 ist ein
natürlich vorkommendes Tumor-Suppressor-Gen, das normalerweise gegen
die Entstehung von Krebs schützt, das aber in mehr als 50%
menschlicher Tumore mutiert und daher inaktiv ist. Die meisten bisher
bekannten Krebstherapien erfordern die Anwesenheit eines aktiven p53
in der Tumorzelle und sind dadurch deutlich in ihrer Wirksamkeit
eingeschränkt.
Weitere Informationen: GPC Biotech AG Petra
Bassen Head of Investor Relations & Corporate Communications
Tel : +49 89 8565 2691 Fax: +49 89 8565 2610 ir@gpc-biotech.com
or visit our homepage at: www.gpc-biotech.com Martinsried/München,
August 23, 2000 Der Vorstand / The Management Board
Cell Genesys and GPC Biotech Report Successful Preclinical Studies for Novel Cancer Gene Therapy Unique Growth Inhibitory Fusion Gene Can Target Multiple Tumor Types
FOSTER CITY, Calif. and MUNICH, Germany, Aug 23, 2000 /PRNewswire via COMTEX/ -- Cell Genesys, Inc. (Nasdaq: CEGE chart, msgs) announced today, in collaboration with GPC Biotech AG (Frankfurt:GPC) that a novel gene therapy employing a unique, proprietary fusion gene, referred to as p27/p16, was capable of killing multiple cancer cell types in preclinical studies. Of particular significance was that tumor cell death was induced in twelve of fourteen human tumor cell types regardless of whether the cells contained a normal or mutated p53 gene-a naturally occurring tumor suppressor gene which typically protects against cancer but is mutated in more than 50 percent of all human cancers. Additionally, the tumor cell killing with p27/p16 gene therapy was selective and did not affect surrounding normal tissue. These data were published in the August issue of the journal, Molecular Therapy, by James G. McArthur, Ph.D., and colleagues at Cell Genesys and GPC Biotech.
In the reported work, a number of preclinical studies were conducted to evaluate gene therapy with p27/p16, a unique fusion gene comprised of two cell cycle inhibitory genes, p27 and p16, which control tumor growth by blocking tumor cell division and inducing tumor cell death. In a series of studies in human tumor models in mice, the p27/p16 gene was delivered to the tumor using an adenoviral gene delivery system. Gene therapy with the p27/p16 fusion gene blocked tumor progression in approximately 50 percent of the treated animals, a result that was highly statistically significant in these experiments (p= .002). The fusion gene demonstrated five to 50-fold greater tumoricidal activity than either of the individual p16 and p27 genes. In addition, p27/p16 gene therapy demonstrated microscopic evidence of an antiangiogenic effect against the tumor with inhibition of tumor blood vessel formation.
"We are encouraged by the preclinical studies performed to date with p27/p16 gene therapy particularly with respect to the breadth of antitumor activity and selectivity for tumor as opposed to normal cells," stated Joseph J. Vallner, Ph.D., executive vice president and chief operating officer at Cell Genesys. "The success of this program together with our expanding research efforts in cancer gene therapy involving antiangiogenesis demonstrates Cell Genesys` growing pipeline of potential cancer products and is an important complement to our program in human clinical trials of GVAX(R) cancer vaccines."
"This project exemplifies the substantial value of GPC Biotech`s extensive estate of issued patents in the field of tumor suppressor genes and growth control, including p27/p16 which is derived from the tumor suppressor genes p16 and p27 and was originally engineered by scientists at Mitotix Inc., now GPC Biotech Inc. In the hands of Cell Genesys with its world class expertise in gene therapy, the p27/p16 fusion gene has exciting potential in the treatment of both cancer and cardiovascular disease," stated Muzammil Mansuri, Ph.D., executive vice president and chief operating officer for GPC Biotech`s Cambridge, MA site.
In 1998, Cell Genesys exclusively licensed a family of cell cycle inhibitor genes from Mitotix, Inc., which was recently acquired by GPC Biotech AG (Munich, Germany). The licensed genes include p16, p27 and novel p27/p16 fusion genes. The collaboration was initially focused on the development of cardiovascular gene therapy products and was expanded to include cancer gene therapy products in 1999. The p16 and p27 cell cycle inhibitor genes, also referred to as cyclin dependent kinase inhibitors (CDKi), play a key role in the regulation of cellular division. Moreover, the p16 gene, a known tumor suppressor gene, has been shown to be missing or mutated in many important cancers. Gene therapy employing p16, p27 and/or the p27/p16 fusion gene could therefore potentially be used to treat a variety of cancers. In addition, such gene therapy may have applicability to the treatment of other diseases characterized by abnormal cell growth such as restenosis, a condition resulting from the excessive growth of blood vessel smooth muscle cells which can arise after angioplasty for coronary artery disease and other cardiovascular disorders. GPC Biotech and Cell Genesys have an ongoing research collaboration for the optimization and testing of the p16, p27 and p27/p16 fusion genes.
Cell Genesys is focused on the development and commercialization of cancer vaccines and gene therapies to treat major, life-threatening diseases. The company is conducting two multicenter Phase II human clinical trials for its GVAX(R) cancer vaccine in prostate cancer, a multicenter Phase I/II trial of GVAX(R) vaccine in lung cancer and expects to initiate additional GVAX(R) vaccine trials in pancreatic cancer, myeloma and leukemia during the coming year. Preclinical stage programs include gene therapy for hemophilia, cancer, cardiovascular disorders and Parkinson`s disease. Cell Genesys` assets outside gene therapy include its approximately 12 percent ownership of Abgenix, Inc. and the company`s licensing program in gene activation technology. For additional information, please visit the company`s web site at www.cellgenesys.com.
GPC Biotech AG is a genomics-driven drug discovery company focused on applying a number of proprietary genomic, proteomic and drug discovery technologies to accelerate the identification and validation of novel drug targets for development of mechanism-based drugs in oncology, infectious diseases and immunology. The proprietary technologies provide life-science companies with a unique "one-stop-shop" resource by fully integrating functional genomics, proteomics and bioinformatics into drug discovery. GPC Biotech has globally-leading cell cycle expertise and a broad intellectual property position with 40 issued patents and over 120 patents pending. Drug discovery alliance partners include: Aventis Pharma, Bayer AG, DuPont Pharmaceuticals, Boehringer Ingelheim, Byk Gulden, Cell Genesys, Maxim Pharmaceuticals, Evotec Biosystems, MorphoSys, Genetica, Gene Alliance, Karo Bio USA and Atugen. GPC Biotech AG is headquartered in Munich, Germany with US subsidiaries GPC Biotech Inc. in Cambridge, MA and GPC Biotech USA in Princeton, NJ. For further information, please visit the corporate web site at www.gpc-biotech.com.
Statements made herein, other than statements of historical fact, including statements about Cell Genesys` progress and results of cancer and other preclinical studies, clinical trials, marketability and success of potential products and nature and growth of product pipelines, corporate partnerships, licenses and intellectual property including that pertaining to gene delivery technology and the company`s patent portfolio are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the continuation of research collaborations with GPC Biotech AG and others, the success of research and development programs, results achieved in future preclinical studies and clinical trials, the regulatory approval process, competitive technologies and products, the scope and validity of patents, corporate partnerships and additional financings. For information about these and other risks which may affect Cell Genesys, please see the company`s Annual Report on Form 10-K dated March 30, 2000 as well as Cell Genesys` reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission.
This press release may contain certain views and forward-looking statements, which include terms such as "believes", "assumes", "expects", "intends" and similar language. Such views and forward-looking statements are based upon currently available information and are subject to known and unknown risks, uncertainties and other factors, as a result of which the actual future financial performance, development or performance of GPC Biotech or the business of GPC Biotech may substantially deviate from the anticipated events presented herein. Such factors include, but are not limited to, the following: competition from other companies, GPC Biotech`s capital needs, financing costs, changes in operating costs, the ability to find and retain qualified staff, uncertainties relating to drug development and obtaining regulatory approvals, uncertainties related to the operations of GPC Biotech and other factors identified in GPC Biotech`s Offering Circular dated May 30, 2000. GPC Biotech is not undertaking any obligation to release publicly any updates to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.
CONTACT: Jennifer Cook Williams, Manager, Corporate Communications of Cell Genesys, Inc., 650-425-4542; or Petra Bassen, Investor Relations and Corporate Communications of GPC Biotech AG in Germany, +49-89-85-65-26-91
Source: Cell Genesys, Inc.
- Cell Genesys currently owns more than 220 patents!
- They have well over 300 patents pending!
- While most biotechs would love to have two years cash on
hand, CEGE has close to 10 (TEN)!!
- Perfect possibility to participate in Abgenix (ABGX).
Cell Genesys holds an 12% ownership!!!
price at the moment: USD 26.--
target price: USD 100.-- end of 2000
- They have well over 300 patents pending!
- While most biotechs would love to have two years cash on
hand, CEGE has close to 10 (TEN)!!
- Perfect possibility to participate in Abgenix (ABGX).
Cell Genesys holds an 12% ownership!!!
price at the moment: USD 26.--
target price: USD 100.-- end of 2000
100$ ist für Ende 2000 ein bißchen viel, Ende 2001 würd`s genügen...
In "Bizarre News"
Japanese Tobacco Company Buys Into Lung Cancer Vaccine
Foster City, Calif. - More than ever before, the lives of cigarette smokers are in the hands of the tobacco companies, and one company in particular. The pharmaceutical unit of Japan Tobacco, the world`s third-largest cigarette company, has invested heavily in a revolutionary lung cancer vaccine being produced by a U.S. firm. Cell Genesys, Inc. announced a payment of $4.5 million following the completion of a clinical trial of GVAX lung cancer vaccine. If successful you`ll be able to buy both your death and life from the same brand.
Naja, 4.5 M$ find ich nicht besonders "heavy".
In "Bizarre News"
Japanese Tobacco Company Buys Into Lung Cancer Vaccine
Foster City, Calif. - More than ever before, the lives of cigarette smokers are in the hands of the tobacco companies, and one company in particular. The pharmaceutical unit of Japan Tobacco, the world`s third-largest cigarette company, has invested heavily in a revolutionary lung cancer vaccine being produced by a U.S. firm. Cell Genesys, Inc. announced a payment of $4.5 million following the completion of a clinical trial of GVAX lung cancer vaccine. If successful you`ll be able to buy both your death and life from the same brand.
Naja, 4.5 M$ find ich nicht besonders "heavy".
Ein Mittel gegen 5 (!!!) Krebsarten. Der Gentherapie-
ansatz von CEGE scheint ja wirklich sehr aussichts-
reich zu sein. Die Testergebnisse sind ja allesamt
hervorragend!
``GVAX® cancer vaccines have now demonstrated antitumor activity in all five cancers tested to date including prostate cancer, lung cancer, pancreatic cancer, kidney cancer and melanoma.``
http://biz.yahoo.com/prnews/000912/ca_cellgen.html
ansatz von CEGE scheint ja wirklich sehr aussichts-
reich zu sein. Die Testergebnisse sind ja allesamt
hervorragend!
``GVAX® cancer vaccines have now demonstrated antitumor activity in all five cancers tested to date including prostate cancer, lung cancer, pancreatic cancer, kidney cancer and melanoma.``
http://biz.yahoo.com/prnews/000912/ca_cellgen.html
Cell Genesys ist uebrigens jetzt bei 29 7/16 .
Was gerade dem Substanzwert entspricht!
(Das heisst es gibt noch:
220 Patente (300 weitere im Zulassungsverfahren)
10 Jahre Cash-burn-ratio (viele groessere Firmen waehren
froh sie haetten 2!)
Automatische Mitbeteiligung an AGBX (ABGX)
(Cege haelt 12% Beteiliung!)
Diese drei Punkte sind gar noch nicht im Preis!
Die Reise geht also NORD-waerts!!
h.r.fox
www.feel.ch
Was gerade dem Substanzwert entspricht!
(Das heisst es gibt noch:
220 Patente (300 weitere im Zulassungsverfahren) 10 Jahre Cash-burn-ratio (viele groessere Firmen waehrenfroh sie haetten 2!)
Automatische Mitbeteiligung an AGBX (ABGX)(Cege haelt 12% Beteiliung!)
Diese drei Punkte sind gar noch nicht im Preis!
Die Reise geht also NORD-waerts!!
h.r.fox
www.feel.ch
Hi alle zusammen. Habe das "Ding" gekauft und werde jetzt ein Paar Jährchen schlafen gehn.
Glaube das CEGE uns allen noch sehr viel freude bereiten wird.
Hat sich schon einer von Euch die Eurofins Aktie angeschaut???
Was haltet Ihr davon......???
Think diferent
Xepher
Glaube das CEGE uns allen noch sehr viel freude bereiten wird.
Hat sich schon einer von Euch die Eurofins Aktie angeschaut???
Was haltet Ihr davon......???
Think diferent
Xepher
Hallo Fans(oder etwa noch nicht?) von CEGE
Schaut mal unter www.trading-division.de nach, die haben eine, wie ich finde sehr gute Analyse über unsere Aktie geschrieben. Lohnt sich das mal zu lesen. Da fühlte ich mich doch wieder bestätigt, dass meine Entscheidung im Mai diese "Dinger" zu kaufen nicht die Schlechteste war!
@Xepher Eurofins weiss ich leider auch nicht viel; meine anderen Bio-Favoriten sind Genesys, MilleniumPH + Medarex.
Viel Freude noch mit CEGE
CarliS
Schaut mal unter www.trading-division.de nach, die haben eine, wie ich finde sehr gute Analyse über unsere Aktie geschrieben. Lohnt sich das mal zu lesen. Da fühlte ich mich doch wieder bestätigt, dass meine Entscheidung im Mai diese "Dinger" zu kaufen nicht die Schlechteste war!
@Xepher Eurofins weiss ich leider auch nicht viel; meine anderen Bio-Favoriten sind Genesys, MilleniumPH + Medarex.
Viel Freude noch mit CEGE
CarliS
Danke Car Li für deinen Tip.(www.trading-division.de)
Sieht gut aus mit unserer "kleinen" Gen-Firma....Ha,Ha
Werde mir noch ein Paar zulegen.
Habe gestern noch die Eurofins gekauft....sehen auch nicht schlecht aus
In meienm Bio-Depot befinden sich jetzt:
Geron
Eurofins
Cell Genesys
Gruß u.Think diferent
Xepher
Sieht gut aus mit unserer "kleinen" Gen-Firma....Ha,Ha
Werde mir noch ein Paar zulegen.
Habe gestern noch die Eurofins gekauft....sehen auch nicht schlecht aus
In meienm Bio-Depot befinden sich jetzt:
Geron
Eurofins
Cell Genesys
Gruß u.Think diferent
Xepher
Hallo Leute,
werde mir am Freitag/Montag einen Biotec ins Depot werfen.
Nachdem Myriad so langsam aber sicher durch die Decke geht
werde ich mich wohl für Cell Genesys entscheiden müssen.
Ansonsten gefallen mir auch ein paar kleinere vielleicht
zukünftige Highflyer recht gut: Onyx, Vical, Xoma.
werde mir am Freitag/Montag einen Biotec ins Depot werfen.
Nachdem Myriad so langsam aber sicher durch die Decke geht
werde ich mich wohl für Cell Genesys entscheiden müssen.
Ansonsten gefallen mir auch ein paar kleinere vielleicht
zukünftige Highflyer recht gut: Onyx, Vical, Xoma.
Konnte nicht warten und habe mir heute Cell Genesys
eingepackt zu 29,10 €.
ICell Genesys ist einer der wenigen aussichtsreichen
Biotecs die klar unterbewertet sind. Allein der 12%-Anteil
an Abgenix beträgt schon 800 Mio € und damit fast die
gesamte Börsenkapitalisierung von CEGE (ca 1 Mrd €).
Weitere Gründe für meine Kaufentscheidung:
Derzeit 230 Patente im Gentherapiebereich, über 300 weitere
Anträge laufen. Im Biotec-Sektor ist eben immer sehr wichtig
wer die Zulassung bekommt und wer weitreichende Patente
besitzt. Auch die Technologieplattform ist sehr interessant,
da sie auch von anderen Unternehmen genutzt werden kann.
Mit einem Cash von 250 Mio $ stehen sie finanziell ohnehin
glänzend da. Der Verlust des letzten Quartals war meines
Wissens nur 0,1 $ je Aktie. Kaum ein anderes Biotec-Unternehmen
steht finanziell so gut da.
Der einzige Nachteil ist, daß die sehr vielversprechenden Medikamente
erst in Phase I und II stehen.
Jedenfalls alles in allem hab ich mich klar für CEGE entschieden,
von über 20 Biotecs die ich zur Zeit näher beobachte.
eingepackt zu 29,10 €.
ICell Genesys ist einer der wenigen aussichtsreichen
Biotecs die klar unterbewertet sind. Allein der 12%-Anteil
an Abgenix beträgt schon 800 Mio € und damit fast die
gesamte Börsenkapitalisierung von CEGE (ca 1 Mrd €).
Weitere Gründe für meine Kaufentscheidung:
Derzeit 230 Patente im Gentherapiebereich, über 300 weitere
Anträge laufen. Im Biotec-Sektor ist eben immer sehr wichtig
wer die Zulassung bekommt und wer weitreichende Patente
besitzt. Auch die Technologieplattform ist sehr interessant,
da sie auch von anderen Unternehmen genutzt werden kann.
Mit einem Cash von 250 Mio $ stehen sie finanziell ohnehin
glänzend da. Der Verlust des letzten Quartals war meines
Wissens nur 0,1 $ je Aktie. Kaum ein anderes Biotec-Unternehmen
steht finanziell so gut da.
Der einzige Nachteil ist, daß die sehr vielversprechenden Medikamente
erst in Phase I und II stehen.
Jedenfalls alles in allem hab ich mich klar für CEGE entschieden,
von über 20 Biotecs die ich zur Zeit näher beobachte.
Schade, daß der Thread hier eingeschlafen ist.
Fehlt wohl noch eine Aktionärsempfehlung
.
Wobei Förtsch allerdings schon alle aussichtsreichen
Biotecs vorgestellt hat, wo bleibt Cell Genesys ?
Fehlt wohl noch eine Aktionärsempfehlung
.Wobei Förtsch allerdings schon alle aussichtsreichen
Biotecs vorgestellt hat, wo bleibt Cell Genesys ?
Gestern gab es eine neue News, dass CEGE (einen Teil?) der
Abgenix-Beteiligung verkaufen will. Wir können ja mal diskutieren,
wie das gesehen werden kann. Den Kurs hat es gut getan, gestern
11% im Plus. Fakt ist, dass der Cashbestand weiter steigen wird
und sich die Frage aufdrängt, was CEGE mit dem Geld machen
will.
CEGE long
Mr. Salami
Abgenix-Beteiligung verkaufen will. Wir können ja mal diskutieren,
wie das gesehen werden kann. Den Kurs hat es gut getan, gestern
11% im Plus. Fakt ist, dass der Cashbestand weiter steigen wird
und sich die Frage aufdrängt, was CEGE mit dem Geld machen
will.
CEGE long
Mr. Salami
Heute Meldung:
CEO Sherwin hat gesagt, CEGE will "shoppen gehen" und ein interessantes Unternehmen
aufkaufen. Geld haben sie ja genug...
Hier der Link:
http://www.ftmarketwatch.com/news/story.asp?guid={5736630C-4…
Mr. Salami
CEO Sherwin hat gesagt, CEGE will "shoppen gehen" und ein interessantes Unternehmen
aufkaufen. Geld haben sie ja genug...
Hier der Link:
http://www.ftmarketwatch.com/news/story.asp?guid={5736630C-4…
Mr. Salami
Ihr dürft Euch freuen, heute gibt es einen deutlichen Upmove.
Es gibt Medienunterstützung:
Cell Genesys Comments on CBS Segment Highlighting Preliminary Clinical Result In GVAX(R) Lung Cancer Vaccine Trial
FOSTER CITY, Calif., Nov. 16 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE - news) today confirmed that a news segment aired Wednesday evening on CBS television highlighting an early positive result from Cell Genesys` ongoing Phase I/II GVAX® lung cancer vaccine clinical trial. It was reported that a patient with advanced non small-cell lung cancer who had failed standard treatments including chemotherapy, has experienced a complete response to vaccine treatment with the disappearance of all previously detected tumors based on standard radiologic studies. The patient was treated by John Nemunaitis, M.D., at U.S. Oncology in Dallas, Texas, which is one of eight clinical trial sites participating in this cancer vaccine trial. Cell Genesys had planned to enroll up to 40 patients in the Phase I/II clinical trial but has recently expanded the trial to include up to 80 patients of which more than 60 patients have been enrolled to date. The overall results of this clinical trial are expected to be available in mid-2001.
``It is important to note that the CBS news report described the results in only one patient. Any definitive conclusions regarding the therapeutic value of GVAX® vaccines for lung cancer must await the completion of further human clinical trials,`` cautioned Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. ``We have chosen to issue our comments in order to provide a context for the information contained in the CBS report and otherwise plan to present the results of this clinical trial at a future scientific meeting.``
http://biz.yahoo.com/prnews/001116/ca_cell_ge.html
Es gibt Medienunterstützung:
Cell Genesys Comments on CBS Segment Highlighting Preliminary Clinical Result In GVAX(R) Lung Cancer Vaccine Trial
FOSTER CITY, Calif., Nov. 16 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE - news) today confirmed that a news segment aired Wednesday evening on CBS television highlighting an early positive result from Cell Genesys` ongoing Phase I/II GVAX® lung cancer vaccine clinical trial. It was reported that a patient with advanced non small-cell lung cancer who had failed standard treatments including chemotherapy, has experienced a complete response to vaccine treatment with the disappearance of all previously detected tumors based on standard radiologic studies. The patient was treated by John Nemunaitis, M.D., at U.S. Oncology in Dallas, Texas, which is one of eight clinical trial sites participating in this cancer vaccine trial. Cell Genesys had planned to enroll up to 40 patients in the Phase I/II clinical trial but has recently expanded the trial to include up to 80 patients of which more than 60 patients have been enrolled to date. The overall results of this clinical trial are expected to be available in mid-2001.
``It is important to note that the CBS news report described the results in only one patient. Any definitive conclusions regarding the therapeutic value of GVAX® vaccines for lung cancer must await the completion of further human clinical trials,`` cautioned Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. ``We have chosen to issue our comments in order to provide a context for the information contained in the CBS report and otherwise plan to present the results of this clinical trial at a future scientific meeting.``
http://biz.yahoo.com/prnews/001116/ca_cell_ge.html
Cell Genesys hat ca 300 Patente im Bereich Gentherapie, eine Plattform die evtl auch von anderen Biotecs genutzt werden kann, gegen kleines Entgeld versteht sich und 20% mehr Cash als die jetzige Börsenkap.... Außerdem schreibt keiner mehr hir, was sagt uns das ? -> Strong buy 
So, nun kann man aber kaufen.
Nicht, weil obiges schon zum 100. Mal veröffentlicht wurde, sondern, weil CEGE ein Kleinod im Schatzkämmerlein hat,
nämlich 10,4 Mio. ABGX-Aktien.
Und nun die einfache Rechnung:
ABGX-Kurs am 30.03.2001 - 23,31 $
ABGX-Kurs heute 38,31 $
Wertzuwachs 15,-- $ x 10,4 Mio.Aktien = 156 Mio. $ mehr im CEGE-Kämmerlein.
Bei 34.321.000 ausstehenden CEGE-Aktien also pro Aktie alleine aus dem ABGX-Zuwachs eine "Wertsteigerung" von
4,50 $ pro CEGE-Aktie!
Und der CEGE-Kurs :
CEGE-Kurs 30.03.2001 - 14,40 $
CEGE-Kurs heute (nur)- 15,80 $
Eine 20-30 % - Chance alleine aus dieser Rechnung, plus eine evtl. Erholung bei den Biotechs könnte zusammen wirkliche 50 % geben !
So, weitere Gedankenspiele sind nun freigegeben !
Viel Glück !
Nicht, weil obiges schon zum 100. Mal veröffentlicht wurde, sondern, weil CEGE ein Kleinod im Schatzkämmerlein hat,
nämlich 10,4 Mio. ABGX-Aktien.
Und nun die einfache Rechnung:
ABGX-Kurs am 30.03.2001 - 23,31 $
ABGX-Kurs heute 38,31 $
Wertzuwachs 15,-- $ x 10,4 Mio.Aktien = 156 Mio. $ mehr im CEGE-Kämmerlein.
Bei 34.321.000 ausstehenden CEGE-Aktien also pro Aktie alleine aus dem ABGX-Zuwachs eine "Wertsteigerung" von
4,50 $ pro CEGE-Aktie!
Und der CEGE-Kurs :
CEGE-Kurs 30.03.2001 - 14,40 $
CEGE-Kurs heute (nur)- 15,80 $
Eine 20-30 % - Chance alleine aus dieser Rechnung, plus eine evtl. Erholung bei den Biotechs könnte zusammen wirkliche 50 % geben !
So, weitere Gedankenspiele sind nun freigegeben !
Viel Glück !
CEGE wurde übrigens letztes Wochenende im Handelblatt aufgeführt,
nähmlich mit dem höchsten Kurs/Cash-Verhältnis. Ich warte mal ab,
wenn Ceregene der nächste Spin-off wird, hoffentlich annähernd
wie Abgenix...
Mr. Salami
nähmlich mit dem höchsten Kurs/Cash-Verhältnis. Ich warte mal ab,
wenn Ceregene der nächste Spin-off wird, hoffentlich annähernd
wie Abgenix...
Mr. Salami
Nachtrag zu meinem vorherigen Posting:
CEGE besitzt 9,1 Mio. Aktien von ABGX.
Habe gerade nochmal in der "Historie" geblättert !
Also 9,1 Mio x Kurszuwachs ABGX 15,-- $ ergibt
136.500.000,-- $ Wertzuwachs alleine durch diese Beteiligung !
CEGE besitzt 9,1 Mio. Aktien von ABGX.
Habe gerade nochmal in der "Historie" geblättert !
Also 9,1 Mio x Kurszuwachs ABGX 15,-- $ ergibt
136.500.000,-- $ Wertzuwachs alleine durch diese Beteiligung !
Hallo,
wer wird denn gleich so optimistisch sein.
Im Handelsblatt stand nämlich auch, daß auf seiten der Anleger leise Zweifel an der Wirksamkeit de Gentherapie
bestehen.
200 Patente sind dann nutzlos,kein Geld, kein garnichts.
Gruß
wer wird denn gleich so optimistisch sein.
Im Handelsblatt stand nämlich auch, daß auf seiten der Anleger leise Zweifel an der Wirksamkeit de Gentherapie
bestehen.
200 Patente sind dann nutzlos,kein Geld, kein garnichts.
Gruß
Hallo Siby,
dass würde mich wirklich mal interessieren, woher das Handelsblatt dies hat. Die
bisherigen Testergebnisse haben eine hohe Wirksamkeit bei sicherer Anwendung
bestätigt. Wahrscheinlich liegt die Sache mit dem Toden bei Versuchen mit
Adenoviren-Gentherapie schwer im Magen. Dass die Gentherapie zukunft hat ist bei
Medizinern unbestritten, die Frage ist nur, welcher
Ansatz sich bei einzelnen Krankheiten durchsetzt.
http://www.wissenschaft.de/sixcms/detail.php?id=56091
dass würde mich wirklich mal interessieren, woher das Handelsblatt dies hat. Die
bisherigen Testergebnisse haben eine hohe Wirksamkeit bei sicherer Anwendung
bestätigt. Wahrscheinlich liegt die Sache mit dem Toden bei Versuchen mit
Adenoviren-Gentherapie schwer im Magen. Dass die Gentherapie zukunft hat ist bei
Medizinern unbestritten, die Frage ist nur, welcher
Ansatz sich bei einzelnen Krankheiten durchsetzt.
http://www.wissenschaft.de/sixcms/detail.php?id=56091
Cell Genesys Begins Second Phase I/II Lung Cancer Trial
FOSTER CITY, Calif. -(Dow Jones)- Cell Genesys started another Phase I/II clinical trial of its experimental GVAX lung cancer vaccine.
In a press release Thursday, Cell Genesys said encouraging interim results in an another ongoing Phase I/II clinical trial prompted the trial, which will evaluate a new format of GVAX. The other trial indicates antitumor activity in advanced stage patients who previously failed chemotherapy or radiation treatment.
The new trial will enroll about 40 patients and will take place at eight medical centers in the U.S.
(This story was originally published by Dow Jones Newswires)
Copyright (c) 2001 Dow Jones & Company, Inc.
All Rights Reserved
Copyright (C) 2001 Dow Jones & Company, Inc. All Rights Reserved.
FOSTER CITY, Calif. -(Dow Jones)- Cell Genesys started another Phase I/II clinical trial of its experimental GVAX lung cancer vaccine.
In a press release Thursday, Cell Genesys said encouraging interim results in an another ongoing Phase I/II clinical trial prompted the trial, which will evaluate a new format of GVAX. The other trial indicates antitumor activity in advanced stage patients who previously failed chemotherapy or radiation treatment.
The new trial will enroll about 40 patients and will take place at eight medical centers in the U.S.
(This story was originally published by Dow Jones Newswires)
Copyright (c) 2001 Dow Jones & Company, Inc.
All Rights Reserved
Copyright (C) 2001 Dow Jones & Company, Inc. All Rights Reserved.
Ich bin am Freitag zu einem Kurs von 21 Euro eigestiegen.Obwohl ich schon seit 3 Jahren in Bios investiere habe ich den Wert echt übersehen. In den letzten Tagen habe ich mich mit ihm beschäftigt und war begeistert.Eine echte Perle!!!ES gibt im Moment fast keine Biotechaktie die Fundamental so fair und günstig bewertet ist!Sollten die Bios eine Rally starten,wird der Wert durch die Decke gehen.Das ist keine Übertreibung oder Pusherei,der Wert ist einfach unterbewertet!!!!!!!!!!!!!!!
Neue Meldung von CEGE, haben die Aquisition von Calydon abgeschlossen!
Cell Genesys Completes Acquisition of Calydon
FOSTER CITY, Calif., Sept. 5 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that it has completed the acquisition of Calydon, Inc., a private biotechnology company focused on developing therapeutic products for cancer. With the addition of Calydon`s technology and product candidates, Cell Genesys will now have three diverse cancer therapeutic product platforms and as many as three late stage product candidates with the potential to enter Phase III clinical trials during the next 18 months. The acquisition, first announced on August 2, 2001, was structured as a stock-for-stock transaction in which Calydon shareholders will receive approximately 935,000 shares of Cell Genesys stock, then valued at approximately $17.4 million, and included the assumption of approximately up to $2.6 million in Calydon liabilities by Cell Genesys.
"We are very pleased to announce the completion of the Calydon acquisition thereby achieving a clearly stated corporate goal to expand our cancer pipeline through a strategic acquisition," stated Stephen A. Sherwin, M.D., chairman and chief executive officer. "We are quite impressed with the results already achieved in human clinical trials of CV706, Calydon`s lead product for prostate cancer, as well as the data obtained in preclinical studies of several other product candidates. We believe this acquisition has added considerable value to our business at a most attractive price."
The cancer product platform developed by Calydon is based on a proprietary technology referred to as ARCA(TM), which employs oncolytic (cancer cell killing) viruses engineered to selectively replicate in and kill targeted cancer cells. The technology utilizes adenovirus, one of the commonly occurring viruses responsible for the common cold. The engineered viruses are delivered either by direct injection into tumors or by intravenous administration and are thousands of times more specific for killing cancer cells than standard chemotherapeutic drugs. Once the ARCA(TM) therapy is delivered to the cancer cells, the virus replicates within the cell until it bursts thereby destroying the cell and spreading the newly created viruses throughout the tumor repeating the cycle in the neighboring cancer cells. The virus specifically targets cancer cells as compared to surrounding tissue, and after destroying the cancer cells, the engineered virus can be cleared by the body`s immune system.
CV706, the lead ARCA(TM)-based product for early stage prostate cancer, is delivered intratumorally similar to radiation seed therapy and demonstrated compelling evidence of antitumor activity in an initial Phase I/II clinical trial. A Phase II study evaluating CV706 in combination with radiation therapy is planned for later this year in preparation for a Phase III trial which is targeted to begin by the end of 2002. A Phase I/II trial for CV787, a product which is delivered intravenously, is under way in advanced prostate cancer patients. Data from this clinical trial are expected to be presented at the European Cancer Conference (ECCO) in late October. Future studies of CV787 would likely include an evaluation of combination therapy with standard chemotherapy for prostate cancer. In addition to prostate cancer, the ARCA(TM)-based technology is demonstrating encouraging results in preclinical studies of colon cancer (CV798), bladder cancer (CV884) and liver cancer (CV890). Cell Genesys expects to manufacture CV706 and other ARCA(TM) products in its GMP (Good Manufacturing Practices) facility located in San Diego, CA
Happy trading
The Red
Cell Genesys Completes Acquisition of Calydon
FOSTER CITY, Calif., Sept. 5 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE) today announced that it has completed the acquisition of Calydon, Inc., a private biotechnology company focused on developing therapeutic products for cancer. With the addition of Calydon`s technology and product candidates, Cell Genesys will now have three diverse cancer therapeutic product platforms and as many as three late stage product candidates with the potential to enter Phase III clinical trials during the next 18 months. The acquisition, first announced on August 2, 2001, was structured as a stock-for-stock transaction in which Calydon shareholders will receive approximately 935,000 shares of Cell Genesys stock, then valued at approximately $17.4 million, and included the assumption of approximately up to $2.6 million in Calydon liabilities by Cell Genesys.
"We are very pleased to announce the completion of the Calydon acquisition thereby achieving a clearly stated corporate goal to expand our cancer pipeline through a strategic acquisition," stated Stephen A. Sherwin, M.D., chairman and chief executive officer. "We are quite impressed with the results already achieved in human clinical trials of CV706, Calydon`s lead product for prostate cancer, as well as the data obtained in preclinical studies of several other product candidates. We believe this acquisition has added considerable value to our business at a most attractive price."
The cancer product platform developed by Calydon is based on a proprietary technology referred to as ARCA(TM), which employs oncolytic (cancer cell killing) viruses engineered to selectively replicate in and kill targeted cancer cells. The technology utilizes adenovirus, one of the commonly occurring viruses responsible for the common cold. The engineered viruses are delivered either by direct injection into tumors or by intravenous administration and are thousands of times more specific for killing cancer cells than standard chemotherapeutic drugs. Once the ARCA(TM) therapy is delivered to the cancer cells, the virus replicates within the cell until it bursts thereby destroying the cell and spreading the newly created viruses throughout the tumor repeating the cycle in the neighboring cancer cells. The virus specifically targets cancer cells as compared to surrounding tissue, and after destroying the cancer cells, the engineered virus can be cleared by the body`s immune system.
CV706, the lead ARCA(TM)-based product for early stage prostate cancer, is delivered intratumorally similar to radiation seed therapy and demonstrated compelling evidence of antitumor activity in an initial Phase I/II clinical trial. A Phase II study evaluating CV706 in combination with radiation therapy is planned for later this year in preparation for a Phase III trial which is targeted to begin by the end of 2002. A Phase I/II trial for CV787, a product which is delivered intravenously, is under way in advanced prostate cancer patients. Data from this clinical trial are expected to be presented at the European Cancer Conference (ECCO) in late October. Future studies of CV787 would likely include an evaluation of combination therapy with standard chemotherapy for prostate cancer. In addition to prostate cancer, the ARCA(TM)-based technology is demonstrating encouraging results in preclinical studies of colon cancer (CV798), bladder cancer (CV884) and liver cancer (CV890). Cell Genesys expects to manufacture CV706 and other ARCA(TM) products in its GMP (Good Manufacturing Practices) facility located in San Diego, CA
Happy trading
The Red
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Ich kann Euch von einem positiven Einzelbeispiel berichten.
Die Schwester von jemanden, den ich von den Yahoo-Boards kenne, ist an bereits metastastiertem Adeno-Lungenkrebs erkrankt.
Da die Heilungsschancen in stage 4 mit Chemo alles andere als gut sind, und sie sowieso sich vor Chemo fürchtete, haben wir ihr alternative Studien vorgeschlagen. Vor allen Dingen hatten wir die von Cell Genesys Phase 2 Studie durchgeführte Studie empfohlen. Das war Anfang Juli.
Das ist seine neueste Meldung:
"She was diagnosed with stage 4 adenocarcinoma 3 months ago so you took a risk by asking … she could be dead by now.
I’m pleased to report happy news … her tumor markers, which were nearly 400 when she was diagnosed, are now down below 30. Her doctor is really pleased and calls her ‘in remission”. She`s still weak but hopes to return to her work as a microbiologist at the University of Victoria by January.
She still has some discomfort caused by a large tumor that had collapsed a lung and flooded her chest cavity with fluid. She may have to have part of that lung removed but it’s clear from the CAT scan that there has been great improvement. A PET scan later this week should determine if that will be necessary.
She’s a fighter with boundless optimism. I’m sure that’s an important component of any recovery from late stage cancer.
:-)
Die Schwester von jemanden, den ich von den Yahoo-Boards kenne, ist an bereits metastastiertem Adeno-Lungenkrebs erkrankt.
Da die Heilungsschancen in stage 4 mit Chemo alles andere als gut sind, und sie sowieso sich vor Chemo fürchtete, haben wir ihr alternative Studien vorgeschlagen. Vor allen Dingen hatten wir die von Cell Genesys Phase 2 Studie durchgeführte Studie empfohlen. Das war Anfang Juli.
Das ist seine neueste Meldung:
"She was diagnosed with stage 4 adenocarcinoma 3 months ago so you took a risk by asking … she could be dead by now.
I’m pleased to report happy news … her tumor markers, which were nearly 400 when she was diagnosed, are now down below 30. Her doctor is really pleased and calls her ‘in remission”. She`s still weak but hopes to return to her work as a microbiologist at the University of Victoria by January.
She still has some discomfort caused by a large tumor that had collapsed a lung and flooded her chest cavity with fluid. She may have to have part of that lung removed but it’s clear from the CAT scan that there has been great improvement. A PET scan later this week should determine if that will be necessary.
She’s a fighter with boundless optimism. I’m sure that’s an important component of any recovery from late stage cancer.
:-)
"Meilensteine"
Monday November 26, 7:01 am Eastern Time
Press Release
SOURCE: Cell Genesys, Inc.
Cell Genesys and JT Modify Agreement for GVAX(R) Cancer Vaccines
FOSTER CITY, Calif., Nov. 26 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE - news) today announced that the company and its collaborator, the pharmaceutical division of Japan Tobacco (JT), have agreed to modify their ongoing collaboration for GVAX® cancer vaccines. The two companies, which previously had a 50/50 worldwide profit sharing arrangement for GVAX® prostate and lung cancer vaccines, will now have a royalty arrangement on sales of GVAX® lung cancer vaccine as well as a royalty arrangement on sales in other cancer indications that may be derived from a certain form of that vaccine, and Cell Genesys will now have full commercial rights for GVAX® prostate cancer vaccine. Under the new agreement, JT will pay Cell Genesys an undisclosed royalty on GVAX® lung cancer vaccine sales in Japan, Taiwan and Korea, and Cell Genesys will pay JT the same royalty on such sales in North America and the rest of the world. The companies will continue to equally share in the development costs of GVAX® lung cancer vaccine products, and JT will continue to pay Cell Genesys milestone payments. Cell Genesys expects no impact on near term revenues relating to this deal modification.
``We are glad to have had the opportunity to modify our GVAX® collaboration agreement with JT in a manner that increases our share of potential sales of GVAX® lung cancer vaccine products,`` stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. ``Cell Genesys is currently evaluating GVAX® vaccines in multiple types of cancer, and we are encouraged by the results of Phase I/II and Phase II clinical trials already reported for lung cancer as well as prostate and pancreatic cancer.``
Cell Genesys` GVAX® cancer vaccines are comprised of tumor cells which have been irradiated and genetically modified to secrete GM-CSF, a hormone which plays a key role in stimulating the body`s immune response to vaccines. The genetically modified tumor cells are used to vaccinate patients to stimulate an immune response against their tumor. GVAX® cancer vaccines have demonstrated antitumor effects against every type of human cancer against which they have been tested to date and are currently being evaluated in five types of cancer -- lung, prostate, pancreatic, leukemia and myeloma. Currently, Cell Genesys is evaluating non patient-specific, off-the-shelf GVAX® vaccines for prostate cancer and pancreatic cancer and patient-specific, individualized vaccines for lung cancer, leukemia and myeloma. The company is currently evaluating two types of individualized GVAX® vaccines for lung cancer which involve either directly altering the patient`s own tumor cells to secrete GM-CSF or mixing the patient`s tumor cells with a non patient-specific GVAX® cell line product which secretes GM-CSF. One of these two forms of GVAX® lung cancer vaccine will be selected for a Phase III trial in advanced lung cancer which is targeted to begin in late 2002.
Monday November 26, 7:01 am Eastern Time
Press Release
SOURCE: Cell Genesys, Inc.
Cell Genesys and JT Modify Agreement for GVAX(R) Cancer Vaccines
FOSTER CITY, Calif., Nov. 26 /PRNewswire/ -- Cell Genesys, Inc. (Nasdaq: CEGE - news) today announced that the company and its collaborator, the pharmaceutical division of Japan Tobacco (JT), have agreed to modify their ongoing collaboration for GVAX® cancer vaccines. The two companies, which previously had a 50/50 worldwide profit sharing arrangement for GVAX® prostate and lung cancer vaccines, will now have a royalty arrangement on sales of GVAX® lung cancer vaccine as well as a royalty arrangement on sales in other cancer indications that may be derived from a certain form of that vaccine, and Cell Genesys will now have full commercial rights for GVAX® prostate cancer vaccine. Under the new agreement, JT will pay Cell Genesys an undisclosed royalty on GVAX® lung cancer vaccine sales in Japan, Taiwan and Korea, and Cell Genesys will pay JT the same royalty on such sales in North America and the rest of the world. The companies will continue to equally share in the development costs of GVAX® lung cancer vaccine products, and JT will continue to pay Cell Genesys milestone payments. Cell Genesys expects no impact on near term revenues relating to this deal modification.
``We are glad to have had the opportunity to modify our GVAX® collaboration agreement with JT in a manner that increases our share of potential sales of GVAX® lung cancer vaccine products,`` stated Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. ``Cell Genesys is currently evaluating GVAX® vaccines in multiple types of cancer, and we are encouraged by the results of Phase I/II and Phase II clinical trials already reported for lung cancer as well as prostate and pancreatic cancer.``
Cell Genesys` GVAX® cancer vaccines are comprised of tumor cells which have been irradiated and genetically modified to secrete GM-CSF, a hormone which plays a key role in stimulating the body`s immune response to vaccines. The genetically modified tumor cells are used to vaccinate patients to stimulate an immune response against their tumor. GVAX® cancer vaccines have demonstrated antitumor effects against every type of human cancer against which they have been tested to date and are currently being evaluated in five types of cancer -- lung, prostate, pancreatic, leukemia and myeloma. Currently, Cell Genesys is evaluating non patient-specific, off-the-shelf GVAX® vaccines for prostate cancer and pancreatic cancer and patient-specific, individualized vaccines for lung cancer, leukemia and myeloma. The company is currently evaluating two types of individualized GVAX® vaccines for lung cancer which involve either directly altering the patient`s own tumor cells to secrete GM-CSF or mixing the patient`s tumor cells with a non patient-specific GVAX® cell line product which secretes GM-CSF. One of these two forms of GVAX® lung cancer vaccine will be selected for a Phase III trial in advanced lung cancer which is targeted to begin in late 2002.
Na, da habe ich gestern wohl gerade richtig wieder zum Einstieg geblasen:
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 76 | ||
| 61 | ||
| 60 | ||
| 36 | ||
| 28 | ||
| 27 | ||
| 17 | ||
| 15 | ||
| 13 | ||
| 12 |
